000070681 001__ 70681 000070681 005__ 20200221144241.0 000070681 0247_ $$2doi$$a10.1155/2016/7029027 000070681 0248_ $$2sideral$$a106048 000070681 037__ $$aART-2016-106048 000070681 041__ $$aeng 000070681 100__ $$aMarengoni, A. 000070681 245__ $$aMultimorbidity: Epidemiology and Models of Care 000070681 260__ $$c2016 000070681 5060_ $$aAccess copy available to the general public$$fUnrestricted 000070681 5203_ $$aDue to the aging of the population, the prevalence of chronic diseases is progressively increasing and most older adults experience the cooccurrence of multiple diseases, a condition known as multimorbidity. It has been estimated that 60% of persons aged 65 years or older are affected by multimorbidity, the reason why the condition is sometimes referred to as the “most common chronic disease” [1]. The appearance of clusters and patterns of patients and diseases in different context and populations group has been also demonstrated [2, 3]. Advanced age, female gender, low socioeconomic status, and education are among the main risk factors for the development of multimorbidity. This suggests, for example, that early life learned risk behaviours may affect the development of this condition [2]. Compared to those with single conditions, persons with multimorbidity are more likely to experience negative health outcomes, including mortality, hospitalization, and functional and cognitive decline, leading ultimately to poorer quality of life and increased care costs. Persons with multimorbidity have the most complex health needs but, due to the current disease-oriented approach in healthcare, they face highly fragmented care that leads to incomplete, inefficient, ineffective, and even potentially harmful interventions [4]... 000070681 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000070681 590__ $$a2.476$$b2016 000070681 591__ $$aBIOTECHNOLOGY & APPLIED MICROBIOLOGY$$b66 / 160 = 0.412$$c2016$$dQ2$$eT2 000070681 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b65 / 128 = 0.508$$c2016$$dQ3$$eT2 000070681 592__ $$a0.885$$b2016 000070681 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1 000070681 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2016$$dQ2 000070681 593__ $$aImmunology and Microbiology (miscellaneous)$$c2016$$dQ2 000070681 655_4 $$ainfo:eu-repo/semantics/other$$vinfo:eu-repo/semantics/publishedVersion 000070681 700__ $$aMelis, R.J.F. 000070681 700__ $$0(orcid)0000-0002-5704-6056$$aPrados Torres, A.$$uUniversidad de Zaragoza 000070681 700__ $$aOnder, G. 000070681 7102_ $$11008$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Medic.Prevent.Salud Públ. 000070681 773__ $$g2016 (2016), 7029027 [2 pp]$$pBioMed res. int.$$tBioMed Research International$$x2314-6133 000070681 8564_ $$s1206313$$uhttps://zaguan.unizar.es/record/70681/files/texto_completo.pdf$$yVersión publicada 000070681 8564_ $$s105074$$uhttps://zaguan.unizar.es/record/70681/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000070681 909CO $$ooai:zaguan.unizar.es:70681$$particulos$$pdriver 000070681 951__ $$a2020-02-21-13:21:54 000070681 980__ $$aARTICLE